Endothelial Glycocalyx in Patients With Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
The luminal side of the entire vasculature is covered with a gel-like polymer called endothelial glycocalyx (EG). EG is important for the transport of molecules in and out of the blood cells and for endothelial function. EG protects the blood vessel wall, is likely to contribute to maintenance of normal blood pressure and the prevention of blood clot formation. Overall it is likely to avoid development of cardiovascular disease. A newly developed blood test, salt-blood test, can measure erythrocyte salt sensitivity and gives information about the condition of EG. EG can also be measured by release of endothelial glycocalyx proteins. Previous studies indicate that this EG is impaired by a number of chronic diseases, including chronic kidney disease. This study investigates the quality of glycocalyx in patients with chronic kidney disease, and compares with the layer in healthy.

Detailed Description
-----------------
The purpose of this study is to gain knowledge about how pronounced the EG are affected in varying degrees of chronic kidney disease compared with healthy controls assessed by salt-blood test release of endothelial glycocalyx proteins. and to see how this correlates to blood pressure (peripheral and central) pulse wave velocity albuminuria coagulation system vasoactive hormones (PRC, p-Ang-II, p-Aldo, p-ANP, p-BNP, p-AVP)

Official Title
-----------------
Endothelial Glycocalyx Evaluated on Release of the Endothelial Glycocalyx Proteins and Salt Blood Test in Patients With Chronic Kidney Disease

Conditions
-----------------
Healthy, Chronic Kidney Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria patients with chronic kidney disease: CKD I-V Age> 18 years 4 diabetics in each CKD-class Dialysis patients must have received dialysis for at least 3 months. Signed consent Exclusion Criteria, patients with chronic kidney disease: Nephrotic syndrome (U-alb> 3.5 g / d, p-alb <30 g / l, and peripheral edema) Alcohol abuse Drug abuse Pregnancy and lactation Hbg <6.2 mmol / l Inclusion criteria, healthy people: Both gender Signed consent Exclusion criteria, healthy people: Arterial hypertension heart, lung, liver, kidney, endocrine og cerebral diseases alcohol, drug or medical abuse smoking pregnancy or breastfeeding blood-donation within a month clinically significant abnormalities in ECG, blood samples or urine samples

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CKD 1<br>Patients with Chronic kidney disease stage 1: Normal kidney function but urine findings or structural abnormalities or genetic trait point to kidney disease. eGFR :90+. 20 patients, maximun 4 patients with diabetes. | |
| CKD 2<br>Patients with Chronic kidney disease stage 2: Mildly reduced kidney function, and other findings (as for stage 1) point to kidney disease. eGFR: 60-89. 20 patients, maximun 4 patients with diabetes. | |
| CKD 3<br>Patients with Chronic kidney disease stage 3: Moderately reduced kidney function. eGFR: 30-59. 20 patients, maximun 4 patients with diabetes. | |
| CKD 4<br>Patients with Chronic kidney disease stage 4: Severely reduced kidney function. eGFR: 15-29. 20 patients, maximun 4 patients with diabetes. | |
| CKD 5<br>Patients with Chronic kidney disease stage 5: Very severe kidney function. eGFR: <15. 20 patients, maximun 4 patients with diabetes. | |
| Dialysis<br>Patients with end stage renal disease in dialysis. 20 patients, maximun 4 patients with diabetes. | |
| Healthy<br>20 healthy people. Control group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Erythrocyte Salt Sensitivity | Blood sample | 1 minute | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Syndecan-1 | blood sample | 1 minute | 
| Heparan Sulfate | blood sample | 1 minute | 
| blood pressure central and peripheral | Mobil-O-Graph | 1 minute | 
| Vasoactive hormones (PRC, Ang-II, Aldo, ANP, BNP, AVP) | blood samples | 1 minute | 
| pulse wave velocity | Mobil-O-Graph | 1 minute | 
| Albuminuria | urine sample | 1 minute | 
| coagulation | blood samples | 1 minute | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Salt blood test, endothelial glycocalyx, chronic kidney disease, syndecan-1, heparan sulfate